These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
277 related articles for article (PubMed ID: 17357290)
1. Soluble Fas, Fas ligand and Bcl-2 in autoimmune thyroid diseases: relation to humoral immune response markers. Myśliwiec J; Okota M; Nikołajuk A; Górska M Adv Med Sci; 2006; 51():119-22. PubMed ID: 17357290 [TBL] [Abstract][Full Text] [Related]
2. Serum CD40/CD40L system in Graves' disease and Hashimoto's thyroiditis related to soluble Fas, FasL and humoral markers of autoimmune response. Mysliwiec J; Oklota M; Nikolajuk A; Waligorski D; Gorska M Immunol Invest; 2007; 36(3):247-57. PubMed ID: 17558708 [TBL] [Abstract][Full Text] [Related]
3. [Age related changes of soluble Fas, Fas ligand and Bcl-2 in autoimmune thyroid diseases]. Myśliwiec J; Okłota M; Nikołajuk A; Górska M Endokrynol Pol; 2007; 58(6):492-5. PubMed ID: 18205105 [TBL] [Abstract][Full Text] [Related]
4. [The assessment of usefulness of humoral markers estimation in patients with autoimmune thyroid diseases]. Myśliwiec J; Okłota M; Nikołajuk A; Górska M Pol Merkur Lekarski; 2005 Nov; 19(113):663-6. PubMed ID: 16498807 [TBL] [Abstract][Full Text] [Related]
5. Analysis of the expression of Fas, FasL and Bcl-2 in the pathogenesis of autoimmune thyroid disorders. Chen S; Fazle Akbar SM; Zhen Z; Luo Y; Deng L; Huang H; Chen L; Li W Cell Mol Immunol; 2004 Jun; 1(3):224-8. PubMed ID: 16219172 [TBL] [Abstract][Full Text] [Related]
6. Identification of apoptotic proteins in thyroid gland from patients with Graves' disease and Hashimoto's thyroiditis. Bossowski A; Czarnocka B; Bardadin K; Stasiak-Barmuta A; Urban M; Dadan J; Ratomski K; Bossowska A Autoimmunity; 2008 Mar; 41(2):163-73. PubMed ID: 18324486 [TBL] [Abstract][Full Text] [Related]
7. The value of estimating serum aproptotic marker concentrations in monitoring and prognosis of 131I--therapy in Graves' disease. Preliminary report. Rogowski F; Parfieńczyk A; Sopotyk A; Budlewski T; Jabłońska E; Kiersnowska-Rogowska B; Szumowski P Nucl Med Rev Cent East Eur; 2004; 7(2):117-22. PubMed ID: 15968597 [TBL] [Abstract][Full Text] [Related]
8. Differential expression of Fas system apoptotic molecules in peripheral lymphocytes from patients with Graves' disease and Hashimoto's thyroiditis. Fountoulakis S; Vartholomatos G; Kolaitis N; Frillingos S; Philippou G; Tsatsoulis A Eur J Endocrinol; 2008 Jun; 158(6):853-9. PubMed ID: 18505906 [TBL] [Abstract][Full Text] [Related]
9. Differential regulation of Fas-mediated apoptosis in both thyrocyte and lymphocyte cellular compartments correlates with opposite phenotypic manifestations of autoimmune thyroid disease. Giordano C; Richiusa P; Bagnasco M; Pizzolanti G; Di Blasi F; Sbriglia MS; Mattina A; Pesce G; Montagna P; Capone F; Misiano G; Scorsone A; Pugliese A; Galluzzo A Thyroid; 2001 Mar; 11(3):233-44. PubMed ID: 11327614 [TBL] [Abstract][Full Text] [Related]
10. Serum concentration of soluble Fas in patients with autoimmune thyroid diseases. Shimaoka Y; Hidaka Y; Okumura M; Takeoka K; Tada H; Amino N Thyroid; 1998 Jan; 8(1):43-7. PubMed ID: 9492152 [TBL] [Abstract][Full Text] [Related]
11. Soluble Fas and soluble Fas ligand levels in patients with acute hepatic failure. Nakae H; Narita K; Endo S J Crit Care; 2001 Jun; 16(2):59-63. PubMed ID: 11481600 [TBL] [Abstract][Full Text] [Related]
12. Serum DNase I, soluble Fas/FasL levels and cell surface Fas expression in patients with SLE: a possible explanation for the lack of efficacy of hrDNase I treatment. Tinazzi E; Puccetti A; Gerli R; Rigo A; Migliorini P; Simeoni S; Beri R; Dolcino M; Martinelli N; Corrocher R; Lunardi C Int Immunol; 2009 Mar; 21(3):237-43. PubMed ID: 19181929 [TBL] [Abstract][Full Text] [Related]
13. Endothelin-1 levels in patients with disorders of the thyroid gland. Tilly N; Schneider JG; Leidig-Bruckner G; Sommer U; Kasperk C Exp Clin Endocrinol Diabetes; 2003 Apr; 111(2):80-4. PubMed ID: 12746758 [TBL] [Abstract][Full Text] [Related]
16. A preliminary clinical application of sICAM-1 RIA in three kinds of thyroid disease. Lu M; Fang P; Zhang Z; He H; Gao S; Hou B; Zheng R; Xiao Q; Yang L Chin Med J (Engl); 2002 Oct; 115(10):1552-5. PubMed ID: 12490109 [TBL] [Abstract][Full Text] [Related]